CTOs on the Move

InMed Diagnostics

www.inmedllc.com

 
InMed Diagnostics is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.inmedllc.com
  • 1401 Shop Rd Suite A
    Columbia, SC USA 29201
  • Phone: 803.227.1481

Executives

Name Title Contact Details

Similar Companies

Omicia

Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes. Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal™, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at more than 300 academic and clinical institutions including the NIH, the University of Oxford, the University of Cambridge, Seattle Children’s Research Institute, Institut Pasteur, University of Maryland Institute for Genome Sciences, and UCSF.

Recombinetics

Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture.

Concert Medical

Concert Medical is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avellino Lab

Avellino is a global leader in precision medicine, focused on innovative genetic diagnostics, gene therapies, and genetic data for modern eyecare practices.

Ideaya Biosciences

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.